VERICI DX PLC

• ⚠

  Confirmation statement overdue

  Due 2026-05-05.

• ⚠

  Material uncertainty over going concern

  The directors believe that additional funding can be obtained to enable the Parent Company and the Group to continue in existence for a period of at least 12 months at the date of approval of these financial statements. However, there is no guarantee that sufficient cash inflows from the Fundraising or other sources will be forthcoming in the timeframe required. This represents a material uncertainty in relation to the funding arrangements of the Group which may result in the Parent Company and the Group not being a going concern.

1. VERICI DX PLC 2020-09-09 → present
2. VERICI DX LIMITED 2020-04-22 → 2020-09-09

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The directors believe that additional funding can be obtained to enable the Parent Company and the Group to continue in existence for a period of at least 12 months at the date of approval of these financial statements. However, there is no guarantee that sufficient cash inflows from the Fundraising or other sources will be forthcoming in the timeframe required. This represents a material uncertainty in relation to the funding arrangements of the Group which may result in the Parent Company and the Group not being a going concern.”

Group structure

1. VERICI DX PLC · parent
   1. Verici Dx Inc 100% · United States of America

Significant events

• “Medicare coverage process for Tutivia™ which extended throughout most of the year and into 2025, we were delighted to announce in April 2025 that this successfully culminated in a comprehensive Local Coverage Determination ("LCD")”
• “global licensing and commercialisation agreement with One Lambda Inc., (a Thermo Fisher Scientific company) ("Thermo Fisher") over our pre-transplant Clarava test, now called PTRA.”
• “Thermo Fisher is investing in new research related to PTRA aimed at identifying the earliest stage at which the test can be utilised before transplantation.”
• “granted them a non-exclusive license for access to a portion of the Company's urine samples. In June 2024, we successfully completed the transfer of a portion of the Company's urine samples.”
• “triggering a further milestone payment of $339,000 in 2024.”
• “announced a collaboration with The Westmead Institute for Medical Research based in Sydney, Australia 2024 on a newly awarded, 4-year federal research grant.”
• “concluded a Material Service Agreement with FBB Biomed, Inc. ("FBB") to offer Research-Use-Only ("RUO") tests for clinicians seeking insights into neurologic diseases such as Multiple Sclerosis and long COVID.”
• “accredited by the internationally recognised College of American Pathology ("CAP")”
• “attained the ISO 27001 certification for Information Security Management System ("ISMS").”
• “launched a new patient-focused education resource on our website.”
• “As announced on 11 June 2025 the Company is proposing to carry out an equity fundraising to extend the Company's cash runway. On 27 May a General Meeting was held that granted the authorities to issue shares once the size and structure of the fundraising is determined.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

2

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +229.6%

  £750,927 → £2,475,167

• Cash

  +53.5%

  £1,960,712 → £3,010,378

• Net assets

  +48%

  £2,637,509 → £3,902,891

• Employees

  +21.1%

  19 → 23

• Operating profit

  +31.1%

  -£6,573,017 → -£4,526,316

• Profit before tax

  +32.7%

  -£6,474,426 → -£4,354,337

• Wages

  +15.5%

  £2,250,556 → £2,598,962

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers